A global consensus initiative has redefined polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its endocrine and metabolic features, which have often been overshadowed by the focus on ovarian cysts. With around 170 million women affected, this condition remains underdiagnosed in up to 70% of cases. The new name signifies the disorder’s multifaceted nature, linking it to cardiovascular, metabolic, and psychological issues. The change is backed by extensive research and is set to have significant healthcare implications worldwide.
